Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability

Pharmaceutical Research

Volumn 16, Issue 1, 1999, Pages 7-15

  Gudmundsson, Olafur S ^a,c   Pauletti, Giovanni M ^a,d   Wang, Wei ^b   Shan, Daxian ^b,e   Zhang, Huijuan ^b,f   Wang, Binghe ^b   Borchardt, Ronald T ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^e AMGEN INC   (United States)

^f University of North Carolina at Chapel Hill   (United States)

Author keywords

Caco 2 cells; Chemical and enzymatic stability; Esterase sensitive prodrugs; Membrane permeability; Opioid peptides; Peptide delivery

Indexed keywords

COUMARIN; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; OPIATE PEPTIDE; PEPTIDASE; PRODRUG;

ARTICLE; BIOAVAILABILITY; CATALYSIS; CELL MEMBRANE PERMEABILITY; DRUG DEGRADATION; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER HOMOGENATE; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; COUMARIC ACIDS; ENDORPHINS; ENZYME STABILITY; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PEPTIDE HYDROLASES; PEPTIDES, CYCLIC; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032937786     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018828207920     Document Type: Article

References (43)

1. V. J. Hruby and C. C. Gehrig. Recent development in the design of receptor specific opioid-peptides. Med. Res. Rev. 9:343-401 (1989).
2. P. W. Schiller. Development of receptor-selective opioid peptide analogs as pharmacological tools and as potential drugs. Handbook Exp. Pharmacol. 104:681-710 (1993).
3. T. J. Abbruscato, S. A. Williams, V. J. Hruby, and T. P. Davis. Blood-to-CNS entry and stability of Biphalin, a unique double-enkephalin analogue and its halogenated derivatives. J. Pharmacol. Exp. Ther. 276:1049-1057 (1996).
4. S. A. Thomas, T. J. Abbruscato, V. S. Hau, T. J. Gillespie, J. Zsigo, V. J. Hruby, and T. P. Davis. Structure-activity relationship of a series of [D-Ala2]deltorphin I and II analogues; in vitro blood-brain barrier permeability and stability. J. Pharmacol. Exp. Ther. 281:817-825 (1997).
5. S. A. Thomas, T. J. Abbruscato, V. J. Hruby, and T. P. Davis. The entry of [D-Penicillamine-2,5] enkephalin into the central nervous system: saturation kinetics and specificity. J. Pharmacol. Exp. Ther. 280:1235-1240 (1997).
6. N. Bodor and L. Prokai. Molecular packaging: peptide delivery to the central nervous system by sequential metabolism. In M. D. Taylor and G. L. Amidon (eds.), Peptide Based Drug Design: Controlling Transport and Metabolism, American Chemical Society: Washington DC, 1995, pp. 317-340.
7. D. L. Greene, V. S. Hau, T. J. Abbruscato, H. Bartosz, A. Misicka, A. W. Lipkowski, S. Hom, T. J. Gillespie, V. J. Hruby, and T. P. Davis. Enkephalin analog prodrugs: assessment of in vitro conversion, enzyme cleavage characterization and blood-brain barrier permeability. J. Pharmacol. Exp. Ther. 277:1366-1375 (1996).
8. A. M. Misicka, A. W. Lipkowski, D. Stropova, H. I. Yamamura, and V. J. Hruby. Syntheses and biological properties of gamma-glutamyl-dermorphin, a prodrug. Life Sci. 58:905-911 (1996).
9. D. Patel, B. D. McKinley, T. P. Davis, F. Porreca, H. I. Yamamura, and V. J. Hruby. Pepide targeting and delivery across blood-brain barrier utilizing triglyceride esters: design, syntheses, and bioactivity. Bioconjug. Chem. 8:434-441 (1997).
10. W. M. Pardridge. Vector mediated peptide drug delivery to the brain. Adv. Drug. Deliv. Rev. 15:109-146 (1995).
11. G. M. Pauletti, S. Gangwar, T. J. Siahaan, J. Aubé, and R. T. Borchardt. Improvement of oral bioavailability: Peptidomimetics and prodrug strategies. Adv. Drug Deliv. Rev. 27:235-256 (1997).
12. G. M. Pauletti, F. W. Okumu, and R. T. Borchardt. Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway. Pharm. Res. 14:164-168 (1997).
13. V. Ramaswami, R. C. Haaseth, T. O. Matsunaga, V. J. Hruby, and D. F. O'Brien. Opioid peptide interactions with lipid bilayer membrane. Biochim. Biophys. Acta 1109:195-202 (1992).
14. R. A. Conradi, P. S. Burton, and R. T. Borchardt. Physicochemical and biochemical factors that influence a drug's cellular permeability by passive diffusion. In V. Pliska, B. Testa and H. V. Waterbeend, (eds), Lipophilicity in Drug Action and Toxicity. VCH Weinheim, Weinheim, 1996, pp. 233-252.
15. P. S. Burton, R. A. Conradi, N. F. Ho, A. R. Hilgers, and R. T. Borchardt. How structural features influence the biomembrane permeability of peptides. J. Pharm. Sci. 85:1336-1340 (1996).
16. T. J. Abbruscato, S. A. Thomas, V. J. Hruby, and T. P. Davis. Blood-brain barrier permeability and bioavailability of a highly potent mu-selective opioid receptor antagonist, CTAP: comparison with morphine. J. Pharmacol. Exp. Ther. 280:402-409 (1997).
17. S. Gangwar, G. M. Pauletti, B. Wang, T. J. Siahaan, V. J. Stella, and R. T. Borchardt. Prodrug strategies to enhance the intestinal absorption of peptides. Drug Discovery Today 2:148-155 (1997).
18. R. Oliyai. Prodrugs of peptides and peptidomimetics for improved formulation and delivery. Adv. Drug Deliv. Rev. 19:275-286 (1996).
19. S. Gangwar, S. D. S. Jois, T. J. Siahaan, D. G. Vander Velde, V. J. Stella, and R. T. Borchardt. The effect of conformation on membrane permeability of an acyloxyalkoxy-linked cyclic prodrug of a model hexapeptide. Pharm. Res. 13:1657-1662 (1996).
20. S. Gangwar, G. M. Pauletti, T. J. Siahaan, V. J. Stella, and R. T. Borchardt. Synthesis of a novel esterase-sensitive cyclic prodrug of a model hexapeptide using an acyloxyalkoxy pro-moiety. J. Org. Chem. 62:1356-1362 (1997).
21. G. M. Pauletti, S. Gangwar, F. W. Okumu, T. J. Siahaan, V. J. Stella, and R. T. Borchardt. Esterase-sensitive cyclic prodrugs of peptides: Evaluation of an acyloxyalkoxy promoiety in a model hexapeptide. Pharm. Res. 13:1615-1623 (1996).
22. G. M. Pauletti, S. Gangwar, B. Wang, and R. T. Borchardt. Esterase-sensitive cyclic prodrugs of peptides: evaluation of a phenylpropioinc acid promoiety in a model hexapeptide. Pharm. Res. 14:11-17 (1997).
23. B. Wang, S. Gangwar, G. M. Pauletti, T. J. Siahaan, and R. T. Borchardt. Synthesis of a unique esterase-sensitive cyclic prodrug system for peptides that utilize a trimethyl-lock-facilitated lactonization reaction. J. Org. Chem. 62:1363-1367 (1997).
24. B. Wang, W. Wang, H. Zhang, D. Shan, and T. D. Smith. Coumarin-based prodrugs 2. Synthesis and bioreversibility studies of an esterase-sensitive cyclic prodrugs of DADLE, an opioid peptide. Bioorg. Med. Chem. Lett. 6:2823-2826 (1996).
25. I. J. Hidalgo, T. J. Raub, and R. T. Borchardt. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal permeability. Gastroenterology 96:736-749 (1989).
26. J. Hughes. Centrally acting peptides; University Park Press, Baltimore, MD, 1977.
27. J. M. Hambrook, B. A. Morgan, M. J. Rance, and C. F. C. Smith. Mode of deactivation of the enkephalins by rat and human plasma and rat brain homogenates. Nature 262:782-783 (1976).
28. G. T. Knipp, N. F. H. Ho, C. L. Barsuhn, and R. T. Borchardt. Paracellular diffusion in Caco-2 cell monolayers: effect of perturbation on the transport of hydrophilic compounds which vary in charge and size. J. Pharm. Sci 86:1105-1110 (1997).
29. R. Hershfield and G. L. Schmir. Lactonization of coumarinic acids. Kinetic evidence for three species of the tetrahedral intermediate. J. Am. Chem. Soc. 95:8032-8040 (1973).
30. K. Takahashi, S. Tamagawa, H. Sakano, T. Katagi, and N. Mizuno. Effect of the ester moiety on stereoselective hydrolysis of several propanolol prodrugs in rat tissues. Biol. Pharm. Bull. 18:1401-1404 (1995).
31. W. N. Aldridge. Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination. Biochem J. 53:110-117 (1953).
32. D. S. Auld and B. Holmquist. Carboxypeptidase A. Differences in the mechanisms of ester and peptide hydrolysis. Biochemistry 13:4355-4361 (1974).
33. C. A. Bailey, P. Bryla, and A. W. Malick. The use of the intestinal epithelial cell model, Caco-2, in pharmaceutical development. Adv. Drug Deliv. Rev. 22:85-103 (1996).
34. P. S. Burton, J. T. Goodwin, R. A. Conradi, N. F. H. Ho, and A. R. Hilgers. In vitro permeability of peptidomimetics: The role of polarized efflux pathways as additional barriers to absorption. Adv. Drug. Deliv. Rev. 23:143-156 (1997).
35. H. Lennernas, K. Palm, U. Fagerholm, and P. Artursson. Correlation between paracellular and transcellular drug permeability in the human jejunum and Caco-2 monolayers. Int. J. Pharm. 127:103-107 (1996).
36. P. B. Watkins. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27:161-170 (1997).
37. B. Wang, K. Nimkar, W. Wang, H. Zhang, D. Shan, O. S. Gudmundsson, S. Gangwar, T. J. Siahaan, and R. T. Borchardt. Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using phenylpropionic acid and coumarinic acid linkers. J. Peptide Res. (in press).
38. O. S. Gudmundsson, S. D. S. Jois, D. G. Vander Velde, T. J. Siahaan, B. Wang, and R. T. Borchardt. The effect of conformation on the membrane permeability of coumarinic acid- and phenylpropionic acid-based cyclic prodrugs of opioid peptides. J. Peptide Res. (in press).
39. J. Hunter and B. H. Hirst. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting drug absorption. Adv. Drug Deliv. Rev. 25:129-157 (1997).
40. M. Sudoh, G. M. Pauletti, W. Yao, P. A. Sprengler, A. B. Smith III, R. Hirschmann, and R. T. Borchardt. Transport characteristics of peptidomimetics. Effect of pyrolinone bioisostere on transport across Caco-2 cell monolayers. Pharm. Res. 15:719-725 (1998).
41. A. Bak, O. S. Gudmundsson, G. J. Friis, T. J. Siahaan, and R. T. Borchardt. Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of chemical and enzymatic stability as well as the transport properties across Caco-2 cell monolayers. Pharm. Res. 16:24-29 (1999).
42. M. Ruwart. Approaches to modulating liver transport of peptide drugs. In M. D. Taylor and G. L. Amidon (eds.), Peptide Based Drug Design: Controlling Transport and Metabolism, American Chemical Society: Washington DC, 1995, pp. 249-262.
43. R. O'Kennedy and R. D. Thornes. Coumarins, Biology, Applications and Mode of Action, John Wiley and Sons, New York, 1997.